Last reviewed · How we verify
5-ALA-SFC
At a glance
| Generic name | 5-ALA-SFC |
|---|---|
| Sponsor | SBI Pharmaceuticals Co, Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment With 5-AminoLEvuliNic Acid Before Cardiac Surgery (PHASE2)
- ALACOVID Study for Vaccinated Subjects (NA)
- Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19 (NA)
- Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19 (NA)
- A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria (PHASE2)
- Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5-ALA-SFC CI brief — competitive landscape report
- 5-ALA-SFC updates RSS · CI watch RSS
- SBI Pharmaceuticals Co, Ltd. portfolio CI